This company seems to have been delisted
Reason: Acquired by Crown Laboratories
Last recorded trade on: April 9, 2025
Source: https://www.businesswire.com/news/home/20250207314086/en/Crown-Laboratories-Completes-Acquisition-of-Revance-Therapeutics
Reason: Acquired by Crown Laboratories
Last recorded trade on: April 9, 2025
Source: https://www.businesswire.com/news/home/20250207314086/en/Crown-Laboratories-Completes-Acquisition-of-Revance-Therapeutics
Revance Therapeutics
RVNC
A$5.60
Share price
0.00%
Change (1 day)
-2.55%
Change (1 year)
Categories
Revance Therapeutics (RVNC) Fails to deliver data
Key failure to deliver metrics for Revance Therapeutics:
- Last SEC data release: 2025-06-30
- Last 15 days FTD volume: N/A
- Last 3 months FTD volume: N/A
- Last year FTD volume: N/A
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for Revance Therapeutics (RVNC) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for Revance Therapeutics (RVNC) - since 2014
Volume in USD (price x number of shares), data since 2014Revance Therapeutics (RVNC) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | A$7.42 M | 7.81% |
| 2024 | A$6.88 M | -84.79% |
| 2023 | A$45.25 M | 383.15% |
| 2022 | A$9.36 M | -6.12% |
| 2021 | A$9.97 M | -56.82% |
| 2020 | A$23.1 M | 668% |
| 2019 | A$3 M | -97.15% |
| 2018 | A$0.10 B | 815.52% |
| 2017 | A$11.51 M | 5.25% |
| 2016 | A$10.93 M | -46.65% |
| 2015 | A$20.5 M | -9.25% |
| 2014 | A$22.59 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 MediciNova MNOV | A$0 M | A$0.08 M | 🇺🇸 USA |
 Johnson & Johnson JNJ | A$10.58 M | A$0.12 B | 🇺🇸 USA |
 Biogen BIIB | A$8.78 M | A$62.76 M | 🇺🇸 USA |